Post-lockdown colds spur sales at Strepsils and Nurofen maker

Reckitt Benckiser records better than expected results after rise in cases of coughs and flu

Reckitt Benckiser enjoyed better than expected results thanks to demand for its treatments for coughs, colds and flu, following a rise in cases after the lifting of global lockdowns.

The Berkshire-based consumer goods company recorded a “sharp improvement” in demand for its Strepsils, Mucinex and Nurofen after social mixing returned, with sales of over-the-counter medicines rising more than 20% in the three months to September.

That drove like-for-like sales up 3.3% in the quarter, compared with the 0.7% drop analysts had expected. As a result, Reckitt said like-for-like revenue for the full year would be up 1 to 3%, up from earlier estimates of 0 to 2%.

Growth will still be lower than last year, when demand for cleaning products during the pandemic sent sales up almost 12%, driven by the disinfectants Dettol and Lysol.

The easing of lockdown measures has also helped lift sales of Durex condoms, which the company also owns. “Strong growth in intimate wellness continued, up mid-single digits, against a strong comparative which saw social restrictions eased in a number of markets,” the company said.

Reckitt shares were the biggest riser in the FTSE 100 index on Tuesday as investors welcomed the results. The shares were up 6.6% to £58.33, but are still about 25% below a pandemic peak of £77.50 in July 2020.

Like other companies, Reckitt warned of a sharp rise in raw materials costs, which were up 10% in the quarter compared with an 8 to 9% rise it had estimated previously. Jeff Carr, the chief financial officer, said he thought inflation would be up a touch in the fourth quarter and perhaps in the low double digits in 2022.

Russ Mould, the investment director at AJ Bell, said there was a lot to like in Reckitt’s results.

“There is a notable hike in sales forecasts, impressively, every division has outperformed expectations and the company has maintained margin guidance despite the inflationary pressures and supply chain issues which it, like all of its peer group are facing,” he said.

Sign up to the daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk

“This is testament both to the strength of its brands which have allowed the company to pass through price increases to its customers and to the ongoing transformation of the businesses under chief executive Laxman Narasimhan.

“Health and hygiene sales are also proving stickier than expected as it becomes clear we’re going to be living with the virus for longer than some anticipated when successful vaccines were first developed.

“And increased mixing has also had the inevitable knock-on effect of meaning we need to reach for those cold and flu over-the-counter remedies.”


Rupert Neate

The GuardianTramp

Related Content

Article image
Dettol maker Reckitt Benckiser’s sales slow as it warns over prices
Consumer goods group, which also makes Nurofen and Durex, says its costs are rising

Joanna Partridge

27, Jul, 2021 @4:31 PM

Article image
Nurofen maker deserves $6m fine for false claims, court told
The Australian consumer watchdog says manufacturer Reckitt Benckiser profited substantially and should be fined accordingly

Calla Wahlquist

13, Apr, 2016 @2:18 AM

Article image
Durex sales surge after end of UK national Covid lockdown
Reckitt Benckiser says condom sales rose more than 10% after restrictions were relaxed

Zoe Wood

20, Oct, 2020 @11:39 AM

Article image
Condom sales down as lockdown limits sex lives, says Durex maker
Physical distancing rules to limit coronavirus spread taking toll on ‘number of intimate occasions’

Rupert Neate

30, Apr, 2020 @12:35 PM

Article image
Massive cyber-attack could cost Nurofen and Durex maker £100m
Reckitt Benckiser says ‘NotPetya’ ransomware – which also affected FedEx and others – disrupted production and deliveries

Angela Monaghan

06, Jul, 2017 @7:38 AM

Article image
‘Sexplosion’? Romance in the air as retailers look to a post-lockdown summer of love
As Covid restrictions ease, firms predict boom in sales of all things romance, from dating apps to condoms and sex toys

Zoe Woodand Sarah Marsh

22, May, 2021 @7:00 AM

Article image
Reckitt Benckiser to pay $1.4bn fine over opioid treatment sales
Nurofen maker reaches deal with US over alleged fraudulent marketing of Suboxone

Sean Farrell

11, Jul, 2019 @8:36 AM

Article image
Three more companies face shareholder wrath over executive pay
Investors revolt over pay at AGMs of Ladbrokes, Reckitt Benckiser and Carillion, following rebellions at BP, Shire and others

Julia Kollewe

05, May, 2016 @4:54 PM

Article image
Nurofen owner Reckitt misses profit forecast amid tough trading
Consumer goods group blames difficulties in developed markets and rising commodity costs

Staff and agency

19, Feb, 2018 @2:52 PM

Article image
Everyone in the housebuilding game is fed up with Persimmon | Nils Pratley
Jeff Fairburn got lucky with long-term incentive shares thanks to George Osborne’s ‘help to buy’ subsidies

Nils Pratley

07, Feb, 2018 @7:42 PM